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Abstract
Many natural product-derived lectins such as the red algal lectin griffithsin (GRFT) have potent in vitro activity against
viruses that display dense clusters of oligomannose N-linked glycans (NLG) on their surface envelope glycoproteins.
However, since oligomannose NLG are also found on some host proteins it is possible that treatment with antiviral lectins
may trigger undesirable side effects. For other antiviral lectins such as concanavalin A, banana lectin and cyanovirin-N (CV-
N), interactions between the lectin and as yet undescribed cellular moieties have been reported to induce undesirable side
effects including secretion of inflammatory cytokines and activation of host T-cells. We show that GRFT, unlike CV-N, binds
the surface of human epithelial and peripheral blood mononuclear cells (PBMC) through an exclusively oligosaccharide-
dependent interaction. In contrast to several other antiviral lectins however, GRFT treatment induces only minimal changes
in secretion of inflammatory cytokines and chemokines by epithelial cells or human PBMC, has no measureable effect on cell
viability and does not significantly upregulate markers of T-cell activation. In addition, GRFT appears to retain antiviral
activity once bound to the surface of PBMC. Finally, RNA microarray studies show that, while CV-N and ConA regulate
expression of a multitude of cellular genes, GRFT treatment effects only minimal alterations in the gene expression profile of
a human ectocervical cell line. These studies indicate that GRFT has an outstanding safety profile with little evidence of
induced toxicity, T-cell activation or deleterious immunological consequence, unique attributes for a natural product-
derived lectin.
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Introduction
HIV-1 is the prototype example of a virus that utilizes an
oligomannose-rich ‘‘glycan shield’’ to occlude functionally impor-
tant domains of the envelope glycoproteins from antibodies, and
evade the immune response [1,2]. Recently Doores et al. [3]
showed that previous measurement of the proportion of
oligomannose NLG relative to complex NLG on recombinant
HIV envelope glycoproteins underestimated the representation of
oligomannose NLG on the native envelope spikes of HIV-1, which
appear to display NLG that are almost exclusively mannose-
terminal Man5–9-GlcNAc2 structures. It is likely that limited access
to the high density of NLG presented on the HIV-1 trimeric
glycoprotein spike by Golgi and endoplasmic reticulum (ER)
a1R2 mannosidases results in an atypical preponderance of
oligomannose glycans rather than complex NLG on HIV-1
surface glycoproteins [3,4,5]. Given that Man5–9-GlcNAc2 struc-
tures are present on less than 4% of the normal human N-glycome
[6,7], dense clusters of oligomannose NLG appear to be a feature
specific to viral envelope glycoproteins, particularly those of
HIV-1 and other immunodeficiency lentiviruses [3]. Consequent-
ly, clusters of oligomannose NLG may be attractive molecular
targets for antiviral drugs and vaccines that act to interrupt HIV-1
infection of target cells by: (i) binding on the virus envelope and
thereby interfering with the structural transitions involved in
receptor and co-receptor docking and virus entry into T-cells and
(ii) blocking access to viral envelope oligomannose NLG targeted
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and macrophages [5,8,9].
It has long been known that a variety of oligomannose-specific
lectins have potent in vitro HIV-1 inhibitory activities, and therefore
have been proposed as microbicide candidates for topical
prophylaxis of HIV-1 infection, and as potential therapeutics
[8,9].However manylectinspossesslymphocyte mitogenicactivities
incompatible with their use as pharmaceuticals, and some are
known human and animal toxins, although the pharmacological
basis for their toxicity is poorly characterized [10,11]. The antiviral
potency of lectins has been correlated to their capacity to bind
multiple glycans simultaneously, often facilitated by their ability to
form dimers and higher order multimers [12,13,14].
The most extensively characterized antiviral lectin is CV-N, a
small protein that exists in both monomeric and homodimeric
configurations and has exceptionally potent anti-HIV activity, in the
low nanomolar range [15]. CV-N targets the Mana1R2Man
terminating glycans displayed in the Man6–9GlcNAc2 structures on
the surface of many viral envelope glycoproteins. Each monomer of
CV-N has the capacity to bind two oligomannose structures [16].
When formulated into a carboxyethylcellulose gel matrix, CV-N
provided almost complete protection against a single high dose
intrarectal or intravaginal challenge with a pathogenic simian-human
immunodeficiency virus (SHIV) [17,18]. However, subsequent in vitro
toxicity studies have raised concerns about the safety of CV-N based
microbicides, finding that in vitro, CV-N has the capacity to promote
secretion of pro-inflammatory cytokines and chemokines from
human peripheral blood mononuclear cells (PBMC), activate
quiescent CD4
+ T-cells, and promote T-cell proliferation
[19,20,21,22]. Similar results were also reported for other lectins
such as microvirin (MVN) (17) and concanavalin A (Con A) (18). It
should be noted that the toxicities of CV-N were much milder in
treated cervical explants in comparison with PBMC [20,21]. The
possible pathogenic consequences associated with these off-target
activities have raised concerns about all other members of the natural
product-based class of antiviral lectins [19,20,21].
GRFT has the most potent and broad spectrum HIV-1
inhibitory activity yet described for any antiviral lectin
[15,23,24,25]. It is a 25 kDa domain-swapped homodimer, with
the first 16 amino acids of each 12.7 kDa monomer completing
the b-prism fold of the other [26]. The homodimer has six
carbohydrate binding pockets, 3 located at each of the opposite
ends of the double-prism homodimer. Atomic resolution crystal
structures of an engineered monomeric GRFT showed that each
monomer can bind to two different nonamannoside molecules
through all three carbohydrate binding sites [13,26]. The antiviral
activity of monomeric GRFT is substantially lower than that of the
homodimeric form, confirming that the GRFT potency is
dependent on its ability to bind multiple oligomannose structures
simultaneously, with strong avidity [13]. We showed recently that
GRFT causes no mitogenic stimulation of PBMC exposed to the
drug [23]. GRFT is fully active in the presence of macaque vaginal
secretions [25], and was shown to have a good safety profile in the
rabbit vaginal irritation model, the Gold Standard preclinical
safety test for vaginal products [23]. Moreover, treatment of
human cervical explants with GRFT induced minimal alterations
in the expression profile of a panel of proinflammatory chemokines
and cytokines. GRFT also strongly inhibited HIV-1 infection of
the cervical explants, and dissemination of HIV-1 infection from
cells resident in the explants to donor T-cells [23]. In the present
study, we performed a comprehensive set of experiments to
interrogate the molecular response of cultured human cervico-
vaginal cells and PBMC to GRFT exposure. Our investigations
employed comparisons between the biological activities of GRFT,
which binds mannose-terminal Man5–9-GlcNAc2, with other
lectins of well-defined carbohydrate binding specificity: (1) CV-
N, which binds Mana1R2Man terminating glycans on Man6–9
-GlcNAc2 structures; (2) phytohemagglutinin A (PHA), targeting
D-galactose and N-acetyl-D-galactosamine on gycan structures; (3)
ConA, specific for terminal (tri) mannose on high mannose glycans
and (4) Pokeweed agglutinin (PKM), which binds N-acetylgluco-
samine. Our studies reveal clear distinctions in biological and
toxicological properties of these lectins, and confirm GRFT’s
superior safety profile for use as a topical microbicide.
Results
GRFT and CV-N binding to human cervical epithelium,
cultured human cervicovaginal cells, and PBMC
We used paraffin-embedded cervical epithelial sections from a 21-
year olddonor to evaluate the binding pattern of fluorescently labeled
GRFT and CV-N to human mucosal epithelia. GRFT
Lec-, a mutant
form of GRFT where we eliminated the lectin activity through
mutation of all six mannose binding sites, was used as a control to
help distinguish binding mediated by the GRFT carbohydrate
binding pockets versus binding associated with other GRFT
structures. The light micrograph in Figure 1A shows an H&E
stained cervical tissue section to orient the observer to the
microanatomy of the human cervical epithelium. Different layers of
the squamous epithelium starting at the basement membrane (basal,
parabasal, intermediate, superficial) are evident; cervical connective
tissue or stroma is beneath the basement membrane. Tissues
incubated with labeled GRFT, GRFT
Lec- and CV-N are shown in
Fig. 1B, C and D, respectively. Minimal fluorescence seen in tissues
exposed to GRFT
Lec- (Fig. 1C) compared with GRFT-stained tissues
(Fig. 1B) confirmed that the binding of GRFT to the outermost layer
of the squamous epithelium was via its carbohydrate binding activity.
There were distinct differences evident in the binding pattern of
GRFT (Fig. 1C) relative to CV-N (Fig. 1D), which bound far more
extensively than GRFT throughout all layers of the squamous
epithelium, basement membrane and underlying stromal tissue.
Additional fluorescence micrographs are provided in Fig. S1. In
cultured cervicovaginal epithelial cells we also observed binding of
both GRFT and CV-N, but not GRFT
Lec- to Ect1/E6E7 cells
(compare Fig. 1E through H), as well as End1/E6E7 and VK2/E6E7
cells (data not shown). We used flow cytometry to evaluate binding of
fluorescently labeled GRFT, GRFT
Lec-andCV-NtohumanPBMC.
Clear shifts in fluorescence intensity show that GRFT (Fig. 1 I) and
CV-N (Fig. 1K) efficiently bind the surface of human PBMC relative
to GRFT
Lec- (Fig. 1J), for which we observed only minimal binding.
Binding of GRFT to the surface of PBMC was significantly reduced
when occluding the glycan binding pockets by pre-incubation with
yeast mannan (Fig. 1I). Interestingly, the binding of CV-N to PBMC
was reduced, but not eliminated, by mannan binding, which implies a
secondmodeofbinding betweenCV-Nandthecellsurface(Fig.1K).
We assume that distinct populations of differentially labeled cells seen
in the flow histograms reflect differences in the amount of labeled
protein that binds different subpopulations of leukocytes in the
unfractionated PBMC samples.
Griffithsin bound to PBMC retains its antiviral activity
When freshly-isolated PBMC were pre-incubated for 24 hrs
with GRFT at various concentrations, washed and then infected
with HIV-1 R5 strain BaL (without adding new compound),
GRFT inhibited viral replication for 9 days of cell culture (Fig. 2).
As a control maraviroc (MVR) at 2 mM was included and this also
showed anti-HIV activity after 9 days in culture, as this compound
is known to bind specifically to the CCR5 receptor. However,
Griffithsin Safety and Efficacy Profile
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antiviral activity in this assay protocol (data not shown).
High concentrations of GRFT are not cytotoxic to
cervico-vaginal cell lines
An MTT assay was used to assess the effects of GRFT on End1/
E6E7, Ec1/E6E7 and VK2/E6E7 cell viability by measuring the
metabolic activity of treated cells. In these experiments (Fig. 3) we
observed no loss in cell viability after a 3 day exposure of the
endocervical and ectocervical cell lines to concentrations of up to
1 mg/ml (84 mM) GRFT, at least 10-times more concentrated than
a likely microbicide formulation [23]. High doses of GRFT did,
however, slightly reduce viability of the vaginal keratinocyte (VK2)
cells. In marked contrast to GRFT, the mannose-specific mitogenic
Figure 1. Analysis of binding specificity of GRFT in comparison with GRFT
lec- and CV-N. In the first column we depict fluorescence
micrographs that show binding of AlexaFluor 488-labeled GRFT (B.), GRFT
Lec- (C.) and CV-N (D.) to paraffin-embedded cervical tissue sections from a
21-year old female. In (A.) we show a hematoxilin and eosin-stained light micrograph of cervical epithelial tissue, showing the general micro-anatomy
of the cervical epithelium. In the second column, we show fluorescent micrographs of cultured human ectocervical cell line Ec1/E6E7 untreated (E.),
and treated with AlexaFluor 488-labeled GRFT (F.), GRFTLec- (G.) and CV-N (H.). The third column shows histograms that depict flow cytometric
analysis of hPMBCs treated with fluorescently labeled GRFT (I.), GRFT
Lec- (J.) and CV-N (K.). The X-axis shows increasing fluorescence intensity from left
to right, the Y-axis shows percentage of labeled cells in the sample.
doi:10.1371/journal.pone.0022635.g001
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towards all three cell lines. As shown in Fig. 3, treatment with 1 mM
ConAkilledapproximately 94% ofthe ectocervical cellsandvaginal
keratinocytes, and 80% of the endocervical cells. PHA, another
lectin known to be mitogenic in vivo and in vitro also caused dose-
responsive cell death, but to a lesser extent than ConA.
GRFT does not stimulate cell proliferation
We previously showed that GRFT exhibits no mitogenic
stimulatory effect in human PBMC, using incorporation of
tritiated thymidine as a marker for cell proliferation [23]. In the
present study we investigated the mitogenic activity of GRFT on
PBMC by flow cytometry, evaluating changes in size and
morphology of cells treated with GRFT in comparison with cells
treated with the vehicle (PBS). Cells treated with 1 or 4 mM GRFT
had flow cytometry profiles similar to the control cells (Fig. 4A, B
and C). In contrast treatment with lectins ConA and PHA at doses
(0.37 mM ConA and 10 mg/ml PHA) that do not negatively affect
cell viability, resulted in completely different flow cytometric plots,
with emergence of a subpopulation composed of larger cells
(higher forward scatter FSC) with perceptibly higher side scatter
(SSC) values gated in Region R2, as shown in Fig. 4D and E. In
addition, a clear decrease in cell number was observed in region
R1 after treatment with ConA and PHA, as quantified in Fig. 4F.
In Fig. 5, we show that GRFT also does not induce cell
proliferation in any of the three cultured human cervical and
vaginal epithelial cells. Cell division was assessed by monitoring
BrdU incorporation in newly synthesized DNA of actively dividing
cervicovaginal cell lines. Treatment with 1 or 8 mM GRFT did not
induce proliferation of any of the cell lines since BrdU counts were
not elevated in comparison with control cells treated with vehicle
alone (PBS). In contrast Pokeweed agglutinin (PKM), a well
characterized mitogen, caused concentration-dependent increase
in cell division, especially in the cervical cell lines End1/E6E7 and
Ect1/E6E7.
Effects of GRFT treatment on PBMC activation markers
To evaluate the effect of GRFT on cell surface markers of
immune activation, we measured expression of the following
membrane proteins: (i) CD69, a marker of activated T-
lymphocytes, considered an ‘‘early’’ marker of T-cell activation;
(ii) CD25, the alpha chain of the IL-2 receptor, upregulated on
Figure 2. Antiviral activity of GRFT-pretreated PBMC for R5
HIV-1 BaL infection. Freshly isolated PBMC from 3 different donors
were pretreated with GRFT (394-0.13 nM) and maraviroc (2 mM) for
24 hrs and then washed and infected with the R5 HIV-1 BaL strain for 9
days. No compounds were added during the infection and viral
replication was measured by p24 Ag specific ELISA in the collected
supernatants.
doi:10.1371/journal.pone.0022635.g002
Figure 3. Effect of GRFT on cervico-vaginal cell viability. Cell viability was evaluated in an MTT assay after 72 hours treatment of Ect1/E6E7
(white), End1/E6E7 (grey) and VK2/E6E7 (black) with different test compounds listed on the X-axis together with their concentrations. Values are
given as mean 6 standard deviation of OD570 – OD630.
doi:10.1371/journal.pone.0022635.g003
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precursors, considered a ‘‘middle’’ marker of T-cell activation; and
(iii) HLA-DR, a component of the type II major histocompatibility
(MHC) complex, and a ‘‘late’’ marker of T-cell activation.
Activated T-cells are highly susceptible to HIV-1 infection, and
hence induction of these markers indicates an undesirable side
effect of lectin treatment of PBMC. PBMC were incubated in the
presence of the test compounds for 72 hours. The vehicle control
was PBS, and positive controls were 10 mg/ml PHA [20], as well
as 0.37 mM ConA, chosen as this concentration was not cytotoxic.
In PBS treated cells, 1.2% PBMC in average were double positive
(CD4
+/CD25
+) and a non significant increase of this population
was observed after incubation in presence of 1 or 4 mM GRFT
(Fig. 6, left panel and Fig. S2A). Treatment with PHA and ConA
resulted in an impressive increase in the number of CD4
+/CD25
+
cells (Fig. 6, left panel and Fig. S2A). In addition, the numbers of
CD4
2/CD25
+ cells were elevated when PBMC were cultured in
presence of PHA or ConA compared to their PBS and GRFT
counterpart (Fig. 6, left panel and data not shown). Similarly,
GRFT treatment did not affect significantly the proportion of
CD4
+/CD69
+ PBMC compared with PBS treatment, whereas
ConA and PHA treatment resulted in an increase of more than 10
times in this sub-population (Fig. 6, middle panel and Fig. S2B).
The numbers of CD4
2/CD69
+ were also elevated after treatment
with ConA and PHA (Fig. 6, middle panel, and data not shown).
In unstimulated cells, about 15% of CD4 positive PBMC
expressed the late activation marker HLA-DR and treatment
with GRFT and ConA did not affect this number in a significant
fashion (Fig. 6, right panel and Fig. S2C). PHA treatment of cells
yielded more than twice the number of CD4
+/HLA-DR
+ cells
(33.4%) compared with unstimulated PBMC.
Cytokine and Chemokine Profile of GRFT-incubated
PBMC
Activation of PBMC may also be reflected by the production of
cytokines and chemokines. To investigate potential activating
properties of GRFT more thoroughly, PBMC were cultured in the
presence of 10 mg/ml GRFT (788 nM) for 72 h. In the culture
supernatant, the concentrations of IL-1a, IL-1ra, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin,
FGF, G-CSF, GM-CSF, IFN-c, IP-10, MCP-1, MIP-1a, MIP-1b,
PDGF-BB, RANTES, TNF-a, and VEGF were determined. A
detailed overview of the cytokine profiles of GRFT-treated PBMC
from multiple blood donors is given in Fig. 7. For reference, we
provide previously published data where PBMC with the same
donor origins were treated with CV-N at 2 mg/ml (182 nM), lower
than the GRFT concentration tested, since higher concentrations
of CV-N proved too toxic to PBMC [19]. The concentration of
the separate cytokines was compared with that of the untreated
PBMC and calculated as a fold increase value. In the previous
studies on PBMC treatment with CV-N and MVN, considerable
variability in the lectin-induced cytokine profile was observed
between the different PBMC donors. Therefore, the fold increase
values obtained from the different donors were divided over
different ranking groups (i.e. 1–3-, 3–10-, 10–100-, 100–500-, and
.500-fold increase), and the number in each rank is given as a
percentage of the total and indicated by a specific color (Fig. 7).
Confirming our data in Fig. 6 that GRFT has very little effect on
lymphocyte activation markers, we also see minimal alterations in
the cytokine and chemokine release for the majority of markers, in
most donor PBMC. This profile indicates that GRFT induces
significantly less response from PBMC than has been previously
reported for CV-N, MVN and ConA [19]. The only chemokine
Figure 4. Flow cytometric evaluation of the mitogenic effect of GRFT on PBMC. Cells were analyzed flow-cytometrically after three days
treatment with PBS (A), 1 mM GRFT (B), 4 mM GRFT (C), 10 mg/ml PHA (D) and 0.37 mM ConA (E). Typical live PBMC population were gated in region R1
and a subpopulation with increased size and higher SSC was gated in region R2. Quantitation of cells in these regions was plotted in F for each test
compound.
doi:10.1371/journal.pone.0022635.g004
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MCP-1 [19]. Although these studies were performed at a later date
than the previously published CV-N and MVN studies, we used
exactly the same donor panel, and the assays were performed in
the same laboratory (D. Schols), justifying comparison between the
experiments.
Validation of the utility of cultured cervico-vaginal cell
lines for detection of off-target effects of GRFT treatment
In our previously published studies, we showed that treatment of
human cervical explants with a range of GRFT concentrations had
no significant effects on expression of a panel of chemokines and
cytokines [23]. In the present studies, we used cultured human
endocervical, ectocervical and vaginal cell lines for more detailed
analysis of potential ‘‘off-target’’ effects of GRFT treatment, since
the cell lines are easier to procure than fresh human cervical tissues,
and experiments with the cell lines are more easily reproduced
without question of variability in genetic background and
physiological conditions of the donor. To validate the utility of
these cell lines (which are immortalized by induction of papilloma-
virus E6 and E7 oncogenes) for analysis of any ‘‘off-target’’ effects of
GRFT treatment, we wished to confirm that the cell lines behaved
similarly to cervical explants after treatment with GRFT, and
ConA, which induced inflammatory responses in our PBMC
studies. We assessed the secretion of many key mediators of
inflammatory responses, including Il-1b, IL-2, IL-6 and IL-8 by all
three cervico-vaginal cell lines. ELISA kits specific for these
cytokines were used for their detection in End1/E6E7, Ect1/
E6E7 and VK2E6E7 cell culture supernatants after 24 h of
incubation in presence of the test compounds. After treatment with
8 mM GRFT, the supernatants showed barely detectable levels of
IL-1b and IL-2, similar to the cells treated withPBS (Fig. 8A and B).
In contrast, all three cell lines produced impressive amounts of these
cytokines upon incubation in presence of ConA (Fig. 8A and B).
Treatment of cervical epithelial cell lines End1/E6E7and Ect1/
E6E7 with GRFT (8 mM), ConA (2 mM) or PBS resulted in similar
levels of IL-6 secretion (Fig. 8C), but in VK2/E6E7, IL-6 release
was approximately three times higher after ConA treatment
compared to PBS, whereas GRFT did not induce the secretion of
this cytokine (Fig. 8C). In the case of IL-8, eachof the three cell lines
showed a distinct pattern of secretion of this cytokine, although no
induction was observed after treatment with 8 mM GRFT: VK2/
E6E7 showed barely detectable levels of IL-8 regardless of the
treatment; IL-8 levels in Ect1/E6E7 were relatively high after PBS
and GRFT treatment and these amounts were about ten times
reduced after treatment with ConA; GRFT treatment resulted in a
slight decrease of IL-8 in End1/E6E7 cell culture supernatants
whereas the concentrations of this cytokine were significantly
increased following treatment with ConA (Fig. 8D). In addition,
GRFT treatment did not alter the production of IL-10, IP-10, MIP-
1b and TGF-a in the cervico-vaginal cells studied (data not shown).
These data indicated that all 3 cell lines behaved as predicted in
response to GRFT and ConA treatment. Since the ectocervical
epithelium is an important point of mucosal transmission of HIV-1,
we focused on the Ect1/E6E7 cell line to derive a more
comprehensive assessment of the effect of GRFT treatment on
cytokine production by the cultured ectocervical cells. A multi-
plexed Luminex assay of the Ect1/E6E7 cell line treated with
GRFT confirmed that the Ect1 cells behaved very similarly to
human cervical explants (data not shown), and validated our use of
these cells in our microarray studies.
Effect of GRFT Treatment on Gene Expression in
Ect1/E6E7 cells
Gene expression in Ect1/E6E7 cells in response to treatment
with GRFT was compared with vehicle (PBS), GRFT
Lec-, CV-N
Figure 5. Effect of GRFT on cervico-vaginal cell proliferation as measured by BrdU incorporation. Cell proliferation was measured by the
incorporation of BrdU in newly synthesized DNA using a colorimetric assay after treatment of Ect1/E6E7, End1/E6E7 and VK2/E6E7 with GRFT (1 or
8 mM), PKM (3.12 or 0.31 mM) or PBS. Cells without BrdU were assessed in the assay as a negative control according to the manufacturer’s intructions.
Values are given as mean 6 standard deviation of the relative cell proliferation rate derived from BrdU incorporated as a percentage of that found in
PBS.
doi:10.1371/journal.pone.0022635.g005
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22635Figure 6. Effect of GRFT on PBMC activation. Cells were incubated for three days in culture medium alone, with 1 mM GRFT, with 4 mM GRFT
and with 10 mg/ml PHA and dual stained using FITC-conjugated anti-CD4 mAb in combination with PE-conjugated anti-CD25 (left panel), anti-CD69
(middle panel) and anti-HLA-DR (right panel). The percentages of receptor positive cell populations are indicated in the individual dot plots.
doi:10.1371/journal.pone.0022635.g006
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0.05 EU per milligram). This was studied using a microarray
experiment in which the whole human genome was represented by
the 41,000 known genes and transcripts [27]. The microarray data
were deposited in the Gene Expression Omnibus database, under
accession number GSE28584. The heat map shown in Fig. 9A
indicates that cells exposed for 24 hours to GRFT
Lec- (1 and
8 mM), and low concentrations of GRFT (0.1 mM ) and CV-N
(0.05 mM) showed comparable gene expression profiles to those
that were incubated in presence of PBS alone. Treatment of Ect1/
E6E7 with 1 mM GRFT resulted in minor changes in the
expression profile while 4 mM GRFT appeared to alter the
expression of many genes but to a much lesser extent compared to
CV-N (0.5 and 4 mM) and ConA at 1 mM (Fig. 9). Thus, the
microarray studies confirm the data showing that GRFT has
substantially lower ‘‘off-target’’ effect in comparison with CV-N
and ConA, although there are clearly several genes that are
regulated by the carbohydrate binding activity of GRFT (compare
with GRFT
Lec-). As predicted from the heat map (Fig. 9A), no
gene was identified as regulated by 0.1 mM GRFT, even when the
cutoff was brought to 1.0. However, a first analysis using
Benjamini-Hochberg low stringency correction with a cutoff of
2.0 yielded 107 and 35 entries as differentially expressed in
samples treated with 1 and 4 mM GRFT, respectively (Fig. 9B).
Treatment with CV-N (0.5 and 4 mM) or ConA (1 mM) resulted in
regulation of impressive numbers of human genes (Fig. 9B). We
then employed stricter criteria by keeping only the positive entries
that showed GRFT concentration dependent gene expression.
This yielded 2 and 32 genes for 1 and 4 mM GRFT, respectively.
The entries which showed an increased gene expression after
treatment with 1 mM GRFT included a gene annotated as
immunoglobulin-like and fibronectin type III domain containing 1
(IGFN1). The entries that were found to be affected by 4 mM
GRFT are summarized in Table S2. Among the 26 genes mapped
by the Ingenuity database, there was overrepresentation of genes
in the following canonical pathways: NRF2-mediated oxidative
stress response (MAF, HMOX1, SOD2), phospholipid degrada-
tion, glycerophospholipid metabolism and Endothelin-1 Signaling
(HMOX1, WISP2), cAMP mediated signaling (CALML5, PKIB)
and acute phase response signaling (HMOX1, SOD2). Further-
more using the Ingenuity software we identified five toxicological
functions with an overrepresentation of genes including liver
hyperbilirubinemia and steatohepatitis, cardiac arteriopathy, renal
and liver necrosis (data not shown). None of these is relevant to
mucosal treatment with GRFT. We used quantitative RT-PCR
(Q-RT-PCR) to validate the microarray results. Expression of 14
Figure 7. Effect of GRFT on the induction of cytokines/chemokines in PBMC. PBMC from healthy donors were incubated for 72 h with
medium only, GRFT or CV-N at 788 nM and 182 nM, respectively. Supernatants were collected and cytokine levels were measured by the Bio-Plex
array system. The fold-increase values of the cytokine concentrations in the supernatant of stimulated PBMC with respect to the concentrations in the
supernatant of untreated cells were determined from 4 and 11 different donors for GRFT and CV-N, respectively. The fold-increase values are divided
in subgroups: 1–3 fold-increase (white squares), 3–10 fold-increase (yellow squares), 10–100 fold-increase (orange squares), 100–500 fold-increase
(dark red squares) and .500 fold-increase (black squares). The amount of fold-increase values for each chemokine/cytokine is given as percentage in
the total amount of donors (Y-axis).
doi:10.1371/journal.pone.0022635.g007
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With the exception of MYCN, all genes studied showed
comparable expression levels in both experimental systems
including microarrays and Q-PCR (Table S3).
Discussion
Natural product lectins have received considerable attention as
potential antiviral drugs, particularly in the context of prevention
of HIV-1 transmission via mucosal surfaces (reviewed recently in
[8]). Although the volume of literature supporting their use as
antivirals in vivo is dwarfed by a comprehensive set of data showing
potent in vitro antiviral activity, there are reports of impressive in
vivo efficacy of CV-N in animal models of HIV-1 prevention
[17,18], influenza prevention and treatment [28], and Ebola virus
prophylaxis and treatment [29], and of GRFT in prevention of
SARS-CoV infection [30]. Despite the myriad of potential
prophylactic and therapeutic applications of antiviral lectins,
enthusiasm for their development as pharmaceuticals is tempered
by a long history of research into natural product lectins, which
characterizes many members of this broad class as erythrocyte
agglutinins, lymphocyte mitogens, and potentially lethal toxins
[10,11]. The pharmacological basis of natural product lectin
toxicity is generally poorly understood, but at a basic mechanistic
level is thought to reside in the lectins’ capacity for multivalency of
binding to cell surface glycans, resulting in cell agglutination and/
or cross-linking of cell surface receptor molecules with consequent
activation of signaling pathways. Why different lectins that bind
identical glycan moieties have quite distinct biological effects in
vitro remains a paradox that is well illustrated by our data which,
show very different in vitro activity profiles of four different
oligomannose-binding lectins: GRFT, CV-N, MVN [19] and
ConA.
Characterization of GRFT is the primary focus of our studies,
but understanding the molecular pharmacology and toxicology of
this potent antiviral lectin is informed by comparison to CV-N, for
which a rich set of in vitro and in vivo data is available. Both
molecules have comparable HIV-1 neutralization activities, with
mean IC80 values against Clade C viruses of 42.764.4 nM for
GRFT and 77.0618.2 for CV-N [15]. Both proteins bind
oligomannose glycans, with GRFT targeting terminal mannose
residues found on Man5–9-GlcNAc2 [13] and CV-N specific for
the Mana1R2Man linkages found on Man6–9-GlcNAc2
[16,31,32]. They thus share overlapping binding specificities,
and should target identical cell surface and viral glycans. If
anything, GRFT would be predicted to bind to a larger number of
glycan targets than CV-N since it can bind pentamannose
structures that lack the a1R2 mannose linkages that CV-N
targets [13]. In this context, it is surprising that CV-N appears to
bind more promiscuously than GRFT throughout the cervical
epithelium and sub-epithelial stroma (Fig. 1A–D, and Fig. S1).
Given that GRFT
Lec- (the carbohydrate-binding deficient form of
GRFT) hardly bound the epithelial sections or cultured cervical
and vaginal epithelial cells (Fig. 1), and GRFT binding to cultured
epithelial cells was blocked by mannan, we conclude that GRFT’s
binding activity to the cell surface is exclusively via its
Figure 8. Effect of GRFT on the secretion of selected key cytokines in cervico-vaginal cell lines. Individual ELISA experiments for
detection of IL-1b (A), IL-2 (B), IL-6 (C) and IL-8 (D) after 24 hours treatment of cervico-vaginal cells with 2 mM ConA (black), 8 mM GRFT (grey) and PBS
(white).
doi:10.1371/journal.pone.0022635.g008
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CV-N binding to the surface of PBMC is not entirely eliminated
by blocking its carbohydrate binding sites with mannan (Fig. 1K).
This implies that its capacity to bind and induce signaling in cells
may not reside entirely in its lectin activities, and supports prior
studies with CV-N [21]. Another important result showed that
GRFT seems to bind somewhat selectively to terminally
differentiated keratinocytes on the epithelial surface, presumably
reflecting presence of optimal glycoprotein binding targets on the
surface of those cells only in the intact epithelium (Fig. 1C and D;
and Fig. S1).
The data presented in Fig. 2 strongly support GRFT’s
candidacy as a microbicide and antiviral, since they show that
GRFT retains antiviral activity even when complexed to the
surface of PBMC. This contrasts with many other lectins or
compounds we have tested in this assay. The most plausible
mechanism that might explain GRFT’s retention of HIV-1 entry
inhibition activity is that fewer than all six carbohydrate binding
sites are occupied when the lectin is docked on cell surface
glycoprotein/s, leaving sites available for binding to the viral
envelope glycoprotein. The crystal structure of GRFT suggests
that the three glycan-binding pockets of each GRFT monomer are
on opposite ends of the double prism homodimer [13], suggesting
that only one monomer of the homodimer is engaged in binding
the cell surface, leaving the ‘‘free’’ monomer competent to bind
and cross-link two oligomannose structures on the surface of HIV-
1. Since the PBMC were washed extensively 24 hours after
treatment and prior to addition of the HIV-1 inoculum, this
suggests that cell surface-bound GRFT irreversibly inactivated the
inoculum, with no evidence of breakthrough infection at 9 days
post infection. This duration of antiviral activity is unprecedented.
Conventionally, antiviral potencies of virus-targeted entry inhib-
itor drugs are measured without washing the cells prior to addition
of viruses. In traditional antiviral assays the IC50 of GRFT against
HIV-1 BaL is 0.2 nM in PBMC, and 0.1 nM against HIV-1 BaL
in monocytes/macrophages (data not shown). Remarkably, the
IC50 for GRFT in the washed PBMC assay (Fig. 2), when the test
agent is applied 24 hours prior to cell washing and infection, is
0.78 nM, showing quite exceptional antiviral activity of GRFT. In
the same assay we show that activity of CCR5 antagonist
maraviroc persists for 24 hrs, although a high concentrations,
but GRFT’s activity persists substantially longer, a property that
may facilitate non-coitally linked administration of microbicides
containing GRFT as an active ingredient.
The cardinal rule in development of an anti-HIV-1 microbicide
must be ‘‘first, do no harm’’. Randomized controlled preclinical
and clinical studies with detergent-based microbicides such as
nonoxynol-9 showed a trend towards evidence of harm, with
increased incidence of not only HIV-1 infection, but also HSV-2
and HPV seen in the experimental arms [33,34,35,36,37]. The
microbicides field therefore requires stringent and extensive in vitro
and in vivo safety studies before human trials initiate. Initial studies
showed that GRFT was not cytotoxic; had no mitogenic activity;
did not induce secretion of chemokine and cytokine-mediators of
inflammation in treated cervical explants; and showed a good
safety profile in the rabbit vaginal irritation test [23,24,25].
The first tissues that GRFT would be exposed to in the human
vagina are keratinocytes in the outer surface of the vaginal and
cervical epithelia. GRFT would also encounter HIV-1 target cells
such as dendritic cells and macrophages resident in the epithelium
and submucosal stroma as well as the primary HIV-1 target cells,
mucosal CD4+ T-cells. In this work we expanded the safety studies
to include analyses of off-target effects derived from GRFT
binding cell surface oligomannose glycans on human PBMC as
well as characterized ectocervical, endocervical and vaginal
keratinocyte cell lines End1/E6E7, Ect1/E6E7 and VK2E6E7,
which were originally established from normal human endocer-
vical, ectocervical, and vaginal epithelia, respectively, and
immortalized by expression of human papillomavirus 16/E6E7
[38]. The immortalized cell lines were shown to have close
resemblance to those of their respective tissues of origin and
primary cultures in their morphological and immunocytochemical
characteristics and therefore proposed for studies dealing with
testing pharmacological agents for intravaginal application [38].
First we evaluated the effects of GRFT on cell viability and we
showed that up to 84 mM GRFT did not decrease cell viability in
the cervical cell lines End1/E6E7and Ect1/E6E7 whereas VK2/
E6E7 was somewhat sensitive to GRFT at high concentrations of
8 mM and above. These results are consistent with the pioneering
work of Mori and coworkers in which no significant cellular
toxicity was found when a variety of human cell types were treated
with GRFT at concentrations of up to 0.783 mM [24]. Since many
lectins have been reported to be mitogenic [39,40], we examined if
GRFT would have an effect on the cervico-vaginal cell
proliferation. Using a colorimetric assay for detection of BrdU in
newly synthesized DNA, we showed that high concentrations of
GRFT did not increase the proliferation of either End1/E6E7,
Ect1/E6E7 or VK2/E6E7. We then evaluated the concentrations
of a panel of cytokines and chemokines in cervico-vaginal cell
culture supernatants using ELISA. We found that high concen-
trations of GRFT had little to no effect on the secretion of
cytokines/chemokines studied including Il-1b, IL-2, IL-6, IL-8,
IL-10, IP-10, MIP-1b and TGFA in all the three cervico-vaginal
cell lines including End1/E6E7, Ect1/E6E7 and VK2/E6E7.
Therefore, our results, taken together suggest that GRFT at these
concentrations does not alter the secretion of the immune system
mediators by cervico-vaginal cells in a significant fashion.
Using the Ect1/E6E7 cell model, we tested GRFT in order to
evaluate its effects on gene expression after over night incubation.
To our knowledge, this is the first study evaluating the effect of an
anti-HIV lectin on gene expression using human genome
microarrays. Our data revealed that exposure to GRFT at
0.1 mM did not affect gene expression whereas treatment of Ect1/
E6E7 with 1 mM GRFT resulted in minor alteration of the gene
expression profile, showing only 2 genes that were considered as
significantly upregulated (cutoff of 2.0). Of note our working
concentrations were very high. For instance, 1 mM corresponds to
about 1,600 times and more than 23,000 times the EC50 found for
the most resistant and the most sensitive HIV-1 strain,
respectively. At higher concentrations of 4 mM GRFT, 32 genes
were considered as differentially expressed (cutoff=2.0). The fold
changes found were less or equal to 3.2. Q-RT-PCR evaluation of
Figure 9. Effect of lectin treatment on gene expression profiles. Cells were treated with CV-N (0.05, 0.5 and 1 mM), ConA (1 mM), GRFT (0.1, 1
and 4 mM), GRFT
Lec- (1 and 8 mM) or PBS before RNA isolation, and hybridization with Agilent total human genome microarrays. The heat map (A.)
was derived from normalized data using GeneSpring GX 10 software. B. A graphical representation of the total number of genes detected as
differentially expressed using Benjamini-Hochberg low stringency correction with a cutoff of 2.0, are reported for CV-N (0.05, 0.5 and 1 mM), ConA
(1 mM), GRFT (0.1, 1 and 4 mM), GRFT
Lec- (1 and 8 mM) and PBS samples.
doi:10.1371/journal.pone.0022635.g009
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presented here. It is unclear what is the biological relevance and
significance of this level of regulation. Using the same cell line
(Ect1/E6E7) Sharkey et al. classified a gene as differentially
expressed when the fold change was more than 2.0 and found a
total of 444 probe sets that fell in this category after treating the
cells 12 h with 10% human seminal plasma [41]. This is in sharp
contrast to treatment with 4 mM GRFT, a level at least 1,000 fold
greater than the average antiviral EC50, which regulated
expression of only 32 genes.
In summary, our data provide further evidence that GRFT, an
exceptionally potent antiviral lectin, has very minor effects on the
molecular physiology of human cells. At this point, the molecular
basis for the distinct biological activities of different antiviral lectins
is uncharacterized, we propose that the specific spatial arrangement
of the carbohydrate binding sites may determine the nature and
extent of cross-linking of cell surface glycoproteins. GRFT clearly
has superior binding and cross-linking activity with the HIV-1
envelope glycoprotein, which displays dense clusters of oligoman-
nose NLG, but does not induce off-target cellular signaling to the
extent that other lectins do. We believe this provides further data in
strong support of focused clinical development of HIV-1 microbi-
cides containing GRFT as an active ingredient.
Materials and Methods
Lectin reagents
Recombinant GRFT was produced in Nicotiana benthamiana
plants. Recombinant CV-N was produced in Escherichia coli.
Methods for expression and purification of both products have
been described previously [23,42]. A synthetic cDNA encoding a
lectin activity-deficient mutant of GRFT, termed GRFT
Lec-,w a s
designed witha conservativeaminoacid substitution ofaspartic acid
to asparagine in each of the 3 carbohydrate binding pockets
identified in the primary amino acid sequence and crystal structures
of GRFT [24,26]. GRFT
Lec- was expressed in N. benthamiana and
purified exactly as described for GRFT [23]. Proteins were purified
to .99%purity, andformulated inphosphatebuffered saline(PBS),
pH 7.4 at 10 mg/ml protein concentration. Endotoxin was
removed from GRFT, GRFT
Lec- and CV-N protein samples using
Detoxi-Gel endotoxin-removing gel gravity flow columns (Thermo
Scientific). Endotoxin levels were measured using the ToxinSen-
sor
TM chromogenic LAL endotoxin assay kit from GenScript
(Piscataway, NJ). Only products with final Endotoxin readings less
than 0.05 Endotoxin Units (EU) per milligram were used in the in
vitro studies, and all dilutions were performed in Endotoxin-free
buffers. GRFT, GRFT
Lec- and CV-N were fluorescently-labeled
with amine-reactive Alexa Fluor 488 carboxylic acid, succinimidyl
ester using a kit from Molecular Probes/Invitrogen, according to
the manufacturer’s specifications. Control lectins Concanavalin A
(ConA), phytohemagglutinin A (PHA) and Pokeweed agglutinin
(PKM) were purchased from Sigma.
Lectin activity measurements using HIV-1 gp120-binding
ELISA
Immobilized HIV-1 gp120 (Protein Sciences Corporation) was
used to measure the lectin activity of purified GRFT, CV-N and
fluorescently labeled conjugates thereof, and to confirm that
GRFT
Lec- lacked gp120 binding activity. Nunc Maxisorp ELISA
plates were coated overnight with 1 mg/ml gp120 (strain IIIB,
Protein Sciences) diluted in PBS. The wells were blocked with 5%
(w/v)non-fatdrymilkinPBS+0.05%Tween(PBS-T;Immunowash,
Bio-Rad) and washed before addition of serial dilutions of lectin
analyte (GRFT, GRFT
Lec-, CV-N or Alexa-Fluor 488-labelled
conjugates thereof) diluted in 16PBS for 1 h. After three washes
with PBS-T, a primary polyclonal antiserum (rabbit anti-GRFT or
CV-N or Alexa-Fluor 488 (Invitrogen), as appropriate) diluted
1:10,000 in PBS was added for 1 h at room temperature. The wells
were again washed before goat anti-rabbit IgG-HRP (Southern
Biotech) was added at a 1:10,000 dilution. Colorimetric values
reflecting HRP activity were derived using KPL SureBlue TMB
Microwell Peroxidase Substrate, with the reaction stopped by
addition of 1 N H2SO4. The plates were read at 450 nm on a
BioTek Synergy HT reader with data collected using Gemini
Software. We confirmed that the labeled products retained lectin
activities comparable to the unlabeled product by gp120-binding
ELISA. We used ELISA with anti-AlexaFluor 488 detection to
measure the total amount of label conjugated to GRFT, GRFT
Lec-
and CV-N,which displayed quantitativelysimilarlabeling efficiency.
Cervico-vaginal cells lines and human PBMC (PBMC)
End1/E6E7, Ect1/E6E7 and VK2/E6E7 are well character-
ized immortalized cell lines derived from normal human
endocervical, ectocervical and vaginal epithelia, respectively
[38]. All 3 cell lines were purchased from the American Type
Culture Collection (ATCC, Rockville, MD). The cervico-vaginal
cell lines were grown as previously described [38] in keratinocyte
serum-free medium (KSFM) supplemented with recombinant
human epidermal growth factor (0.1 ng/ml), bovine pituitary
extract (50 mg/ml), calcium chloride (0.4 mM) and an antibiotic
cocktail composed of penicillin and streptomycin at final
concentrations of 100 U/ml and 100 mg/ml, respectively. Re-
agents were obtained from Invitrogen (SanDiego CA, or from
Sigma Chemical Company). Cryopreserved human PBMC used
in assays of inflammatory cytokines and chemokines were
purchased from SeraCare life Sciences Inc. (Milford, MA) and
were immediately cultured for the experiments in RPMI 1640
supplemented with 10% fetal bovine serum (FBS) and the
penicillin-streptomycin antibiotic cocktail (to 100 U/ml and
100 mg/ml final concentrations, respectively).
Microscopical analysis of lectin interaction with human
cervical tissues and cultured cervicovaginal cells
Slides with paraffin embedded human cervical tissue sections
from a healthy 21 year old female (US Biomax, Inc.) were
deparaffinized and rehydrated. Alexa-Fluor 488-labelled proteins of
interest were added to the slidesand incubatedovernight at 4uCi na
humidity chamber. The slides were rinsed with PBS twice for
10 minutes and coverslipped using VectaShield Mounting Media
with DAPI (Vector Laboratories, Burlingame, CA). For light
microscopy, tissue sections were stained with hematoxylin and
eosin by standard methods. Ect1/E6E7, End1/E6E7 and VK2/
E6E7 cultured cells were seeded onto eight-well Lab-Tek chamber
slides (Nalgene Nunc) in duplicate at 10,000 cells per well and
allowed to incubate at 37uC with 5% CO2. After eight hours the
fluorescently labeled proteins of interest were added to the wells and
incubated overnight at 37uC with 5% CO2. The slides were washed
twice for 10 minutes with PBS and coverslipped using VectaShield
Mounting Media with DAPI (Vector Laboratories, Burlingame,
CA). Slides were visualized using the Axio Observer Z1 microscope
with ApoTome assembly (Carl Zeiss, Thornwood, NY).
Analysis of lectin interaction with PBMC surface
molecules by flow cytometry
Human PBMC (SeraCare Life Sciences, MD) were thawed and
seeded onto 48-well culture plates (CellTreat, MA) at 2.5610
5 cells per
well. Three dilutions of each Alexa-Fluor 488-labeled protein were
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Samples were also prepared with 5 and 10 mg of mannan (Sigma, St.
Louis MO) at each protein dilution. All samples were analyzed in
duplicate. Following incubation, cells were briefly trypsinized (TrypLE
Express, Gibco) and placed in 5 mL polystyrene tubes (BD Falcon,
MA). Cells were washed twice with PBS and analyzed using the BD
FACSAria (BD Biosciences, NJ) flow cytometer.
Antiviral activity assay in PBMC
Freshly isolated PBMC were cultured in the presence of GRFT,
CV-N and maraviroc for 24 hrs. Then the cells were collected,
washed in culture medium, suspended in RPMI medium with
2 ng/ml IL-2 and seeded in a 48-well flat bottom plate (5610
5
cells in 450 ml) and 50 ml of the CCR5-tropic clade B HIV-1 BaL
stock was added at 100 TCID50. The supernatant of each sample
was collected after 9 days and viral replication measured by a
specific p24 Ag ELISA (Perkin Elmer, Zaventem, Belgium).
Cell viability assays
Viability of cervico-vaginal cell lines was measured using a
colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetra-
zolium bromide] assay kit from BIOTIUM Inc. (Hayward, CA)
following the manufacturer’s instructions. Briefly, 10
4 cells per well
were seeded (96 well plates), the test reagents added and the
cultures incubated for three days in a humid environment with 5%
CO2 at 37uC. Afterwards, 10 ml of MTT solution were added to
each well followed by 4 hours incubation at 37uC. Then the
medium was gently removed and the insoluble purple formazan
product dissolved in DMSO to yield a colored solution which
absorbance was read at 570 nm with a background at 630 nm.
Mitogenicity assays
Proliferation of cervicovaginal cell lines was evaluated by
bromodeoxyuridine (BrdU, a thymidine analog) incorporation in
newly synthesized DNA using a Cell Proliferation ELISA kit from
Roche, according to the manufacturer’s instructions. For human
PBMC, cells were treated with GRFT for three days and analyzed
by flow cytometry for any changes in size and/or morphology using
forward scatter (FSC) and side scatter (SSC) with a FACSCalibur
(BD, San Jose, CA) counting 10,000 events per sample. Data were
acquired and analyzed using CellQuest Pro from BD. ConA
(0.37 mM), PHA (10 mg/ml) and PBS were used as controls.
Evaluation of cellular activition markers
Three day old PBMC were analyzed flow-cytometrically after
dual fluorescent staining with anti-mouse antibodies purchased
from BD Pharmingen (San Diego, CA). Briefly, cell cultures were
transferred from plates to a 5 ml round bottom tubes and washed
with PBS containing 5% inactivated FBS (washing solution). After
10 min blocking with purified rat anti-mouse CD16/CD32
(Mouse BD Fc Block), cells were incubated in dark with FITC-
conjugated anti-CD4 mAb in combination with PE-conjugated
anti-CD25, anti-CD69 or anti HLA-DR mAb for 30 min on ice.
Finally PBMC were washed and analyzed with a FACSCalibur
(BD, San Jose, CA), counting 10 000 events per sample. Data were
acquired and analyzed using CellQuest Pro from BD. ConA
(0.37 mM) and PHA (10 mg/ml), and PBS were used as positive
and negative controls, respectively.
Immunoassays for cytokine detection in cultured
cervicovaginal cell supernatants
Multiplex immunoassays were carried out on a Bio-Plex
instrument (Biorad) using a Milliplex Human Cytokine/Chemo-
kine 42-plex Luminex bead-based assay (Millipore), following the
manufacturer’s instructions. Each luminex immunoassay was
repeated three times. The kit allows simultaneous quantification
of human- epidermal growth factor (EGF), eotaxin, fibroblast
growth factor-2 (FGF-2), fms-like tyrosine-kinase 3 ligand (Flt-3
ligand), fractalkine, granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage-CSF (GM-CSF), GRO, interferon-
a2(IFN-a2), IFN-c, interleukin-10 (IL-10), IL-12 (p40), IL-12
(p70), IL-13, IL-15, IL-17, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-9, IL-1 receptor antagonist (IL-1Ra), interferon-
inducible protein-10 (IP-10), monocyte chemoattractant protein-1
(MCP-1), MCP-3, macrophage-derived chemokine (MDC), mac-
rophage inflammatory protein-1a (MIP-a), MIP-1b, platelet-
derived growth factor-AA (PDGF-AA), PDGF-AB/BB, regulated
upon activation normal T-cell expressed and secreted (RANTES),
soluble CD40 ligand (sCD40L), soluble IL-2Ra (sIL-2Ra),
transforming growth factor a (TGF-a), tumor necrosis factor-a
(TNF-a), TNF-b and vascular endothelial growth factor (VEGF).
Supernatants collected from Ect1/E6E7 after 24, 48 and 72 hours
of culture in presence of test compounds were studied in the
multiplex-immuno assays and data were analyzed using the
Luminex 6PONENT
R software. Individual ELISA experiments
were performed on End1/E6E7, Ect1/E6E7 and VK2E6E7 cell
culture supernatants collected after 24 hours of incubation in
presence of GRFT or controls. ELISA Ready-SET-Go! Kits
designed for accurate and precise measurement of human IL-1b,
IL-2, IL-6 and IL-10 were purchased from eBioscience, Inc.
QuantikineH ELISA kits from R&D Systems, Inc. were used for
the detection of IL-8, IP-10 and TGF-a. MIP-1b was quantified
using an ELISA kit from Cellsciences. All ELISAs were performed
according to the manufacturer’s specifications.
Bio-Plex Cytokine Assay in human PBMC supernatants
PBMC from multiple blood donors [19] were cultured for 72 h
in presence of 10 mg/ml GRFT (788 nM). In the culture
supernatants, the concentrations of IL-1a, IL-1ra, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17,
eotaxin, FGF, G-CSF, GM-CSF, IFN-c, IP-10, MCP-1, MIP-1a,
MIP-1b, PDGF-BB, RANTES, TNF-a, and VEGF were
determined by the Bio-Plex 200 system (Bio-Rad) and Bio-Plex
Human Cytokine 27-plex assay according to the manufacturer’s
instructions. Data were generated with Bio-Plex Manager 4.1
software.
Gene expression analysis in Ect1/E6E7 cells
Cultured Ect1/E6E7 cells were incubated with dilutions of
GRFT, GRFT
Lec-, CV-N, ConA, or vehicle only (PBS, pH 7.4)
for 16 hours. The cells were lysed using a Qiagen Qiashredder,
and total RNA was extracted using a Qiagen RNeasy Mini Kit.
Total RNA was quantified spectrophotometrically and the sample
quality was checked on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Wilmington, De). 200 ng RNA were used to
generate cyanine 3 (Cy3) cRNA with the aid of Low RNA Input
Linear Amplification kit, one-color (Agilent Technologies, Wil-
mington, De) according to the manufacturer’s instructions.
1.65 ug of each labeled cRNA sample were fragmented at 60uC
for 30 min using an Agilent Gene Expression Hybridization kit
(Agilent Technologies, Wilmington, De) followed by hybridization
to a whole human genome Agilent oligonucleotide slide containing
four high-definition 44 K microarray (Agilent Technologies,
Wilmington, De) at 65uC for 17 hours. After hybridization, the
slides were washed with Agilent gene expression wash buffers
(Agilent Technologies, Wilmington, De) and scanned using an
Agilent G2565BA microarray scanner system (Agilent Technolo-
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extracted with the Feature Extraction software v 9.5.1 (Agilent
Technologies, Wilmington, De) and the raw data imported into
GeneSpring GX 10 software (Agilent Technologies, Wilmington,
De) for normalization and further analysis to yield a list of
differentially expressed genes. Benjammini and Hocheberg
correction controlling the false discovery rate FDR [43,44,45]
was used and we considered only a fold change of at least 2.0
compared to the PBS treated samples to represent a meaningfully
altered gene expression [41,46,47]. The raw microarray data were
uploaded into the Gene Expression Ominbus (GEO) database, a
MIAME-compliant database as detailed on the MGED Society
Website http://www.mged.org/Workgroups/MIAME.html. The
GEO accession number is GSE28584. Further analysis of the
regulated genes was carried out using the Ingenuity knowledge
database (Ingenuity Systems Inc., Redwood City, CA) yielding
putative toxicological functions, and canonical pathways. Quan-
titative RT-PCR was carried out in order to validate the
microarray results. First strand cDNA was reverse transcribed
from 250 ng RNA employing a High Capacity RNA-to-cDNA Kit
(Applied Biosystems) following the manufacturer’s instructions.
Optimal amounts of template cDNA were added to a reaction
mixture containing 10 mlo f2 6TaqManH Gene Expression
Master Mix (Applied Biosystems) and water to 20 ml and this
mixture was used to set the PCR reactions in TaqManH Array
Standard 96 well Plates (Applied Biosystems). These plates contain
pre-spotted individual TaqManH Gene Expression Assays for
detection of human cysteine-aspartic acid protease (caspase14,
CASP14), beta defensin 103A (DEFB103A), immunoglobulin-like
and fibronectin type III domain containing 1 (IGFN1), interleukin-
1b (IL-1b), IL-2, IL-6, IL-8, IL-10, IL-33, IP-10, V-Myc
Myelocytomatosis Viral Related Oncogene (MYCN), thyroglob-
ulin (TG ), TGFA, tripartite motif-containing 63 (TRIM63) as well
as the house keeping genes 18 S and beta actin (ACTB). Individual
probes used in these experiments are described in Table S1. PCR
amplification was performed in an 7900HT Fast Real-Time PCR
System (AppliedBiosystems) as follows: initial activation step
(95uC, 20 min), 40 cycles (95uC, 1 min) and 20 min at 60uC.
SDS 2.3 or RQ Manager 1.2 software from Applied Biosystems
was used to evaluate the cycle threshold (Ct) for each reaction,
which is the cycle number at which 50% maximal amplicon
synthesis is achieved. Ratios were derived as proposed elsewhere
[48].
Statistical analyses
Group means and standard deviations were derived from the
values obtained in three individual replicates. Statistical signifi-
cance was analyzed by a one-way analysis of variance (ANOVA)
and student’s t-test unless otherwise stated, using GraphPad
software (San Diego, CA). Differences were considered statistically
significant if p,0.05. For microarray data, the statistical analysis
was carried out as described in the Gene expression analysis methods
above.
Supporting Information
Figure S1 Analysis of binding specificity of GRFT in
comparison with GRFT
lec- and CV-N. In the first column we
depict the identical fluorescence micrographs to Fig. 1, these show
binding of AlexaFluor 488-labeled GRFT (B.), GRFT
Lec- (C.) and CV-
N (D.) to paraffin-embedded cervical tissue sections from a 21-year old
female. In (A.) we show a hematoxilin and eosin-stained light
micrograph of cervical epithelial tissue, showing the general micro-
anatomy of the cervical epithelium. We have provided additional
fluorescence micrographs of tissues stained with labeled GRFT (B2 and
B3), GRFT
Lec- (C2 and C3) and CV-N (D2 and D3).
(TIF)
Figure S2 Quantitation of the effect of test compounds
on the expression of activation markers in CD4 positive
PBMC. Percentages of double positive PBMC are reported for
cells after 3 days treatment with PBS, 1 mM GRFT, 4 mM GRFT,
10 mg/ml PHA and 0.37 mM ConA and dual staining using FITC-
conjugated anti-CD4 mAb in combination with PE-conjugated
anti-CD25 (A), anti-CD69 (B) and anti-HLA-DR (C).
(TIF)
Table S1 Genes used in Q-PCR experiments with correspond-
ing TaqMan assay identities.
(DOC)
Table S2 List and fold changes (FC) of mapped genes
differentially expressed after treatment with 4 mM GRFT.
(DOC)
Table S3 Relative expression of selected genes after treatment
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